Quantum BioPharma Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
QNTM Nasdaq 2834 www.quantumbiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quantum BioPharma Ltd.

Quantum BioPharma (QNTM) Advances MS Imaging Study With Encouraging Preliminary Results - Aug 3rd, 2026 1:15 pm
Quantum BioPharma Announces Closing of Debt Settlement - Jul 29th, 2026 10:18 pm
Quantum BioPharma (QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans - Jul 28th, 2026 12:35 pm
Quantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions - Jul 22nd, 2026 12:30 pm
Quantum BioPharma Announces Intention to Settle Debt - Jul 20th, 2026 5:00 pm
Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy - Jul 15th, 2026 12:45 pm
Why Quantum BioPharma (QNTM) Is 'One to Watch' - Jul 10th, 2026 12:30 pm
Quantum BioPharma Provides Corporate Update - Jul 7th, 2026 5:00 pm
Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - Jul 1st, 2026 1:00 pm
Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - Jun 29th, 2026 1:30 pm
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy - Jun 25th, 2026 6:30 am
Quantum BioPharma (QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials - Jun 23rd, 2026 1:45 pm
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach - Jun 23rd, 2026 6:30 am
Quantum BioPharma (QNTM) Advances Proprietary Therapy for MS Treatment - Jun 9th, 2026 12:51 pm
Quantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - Jun 4th, 2026 1:30 pm
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - Jun 2nd, 2026 1:50 pm
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. - Jun 2nd, 2026 6:00 am
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns - Jun 2nd, 2026 5:40 am
Quantum BioPharma (QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study - May 19th, 2026 12:05 pm
Quantum BioPharma Reaches Halfway Point in Patient Enrollment in Imaging Study With MGH - May 19th, 2026 5:21 am